Prothena Corp. (PRTA) Insider Karin L. Walker Sells 5,000 Shares
Prothena Corp. (NASDAQ:PRTA) insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 13th. The shares were sold at an average price of $54.23, for a total transaction of $271,150.00. Following the completion of the sale, the insider now owns 3,000 shares in the company, valued at approximately $162,690. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Prothena Corp. (NASDAQ:PRTA) opened at 53.55 on Monday. Prothena Corp. has a 52 week low of $28.20 and a 52 week high of $76.42. The company’s 50-day moving average is $57.27 and its 200-day moving average is $49.19. The company’s market cap is $1.84 billion.
Prothena Corp. (NASDAQ:PRTA) last posted its earnings results on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.27. The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.39 million. Prothena Corp. had a negative return on equity of 28.15% and a negative net margin of 8,628.11%. The firm’s revenue was up 22.2% on a year-over-year basis. On average, analysts anticipate that Prothena Corp. will post ($4.25) EPS for the current fiscal year.
A number of analysts have weighed in on PRTA shares. Royal Bank Of Canada restated a “buy” rating on shares of Prothena Corp. in a research report on Wednesday, June 22nd. Wedbush reiterated an “outperform” rating and set a $77.00 price target on shares of Prothena Corp. in a report on Tuesday, July 5th. Credit Suisse Group AG reiterated a “buy” rating on shares of Prothena Corp. in a report on Tuesday, July 12th. Barclays PLC lifted their price target on shares of Prothena Corp. from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Thursday, August 4th. Finally, Zacks Investment Research lowered shares of Prothena Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, October 4th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $76.80.
Hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its stake in Prothena Corp. by 197.8% in the first quarter. BlackRock Inc. now owns 2,656 shares of the company’s stock worth $110,000 after buying an additional 1,764 shares during the period. Societe Generale bought a new position in shares of Prothena Corp. during the second quarter worth approximately $111,000. BNP Paribas Arbitrage SA raised its position in shares of Prothena Corp. by 49.9% in the second quarter. BNP Paribas Arbitrage SA now owns 4,039 shares of the company’s stock worth $141,000 after buying an additional 1,344 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Prothena Corp. by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 4,021 shares of the company’s stock worth $141,000 after buying an additional 493 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in shares of Prothena Corp. during the second quarter worth approximately $195,000.
Prothena Corp. Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Stock Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related stocks with our FREE daily email newsletter.